Engineering the Next Generation of Single‑Domain Antibodies
Akeagen’s CaMouse platform enables in‑vivo generation of heavy‑chain‑only antibodies and rapid VHH discovery through integrated workflows: mRNA immunization, phage & yeast display, and single B‑cell isolation.
About Akeagen
About us
Akeagen Inc. is a biotechnology company based in Irvine, California, focused on enabling fast, precise, and scalable discovery of single‑domain antibodies (VHHs) for therapeutics and life‑science applications. Our proprietary CaMouse platform and modular discovery stack streamline antigen presentation, selection, and characterization to compress timelines from months to weeks.
At‑a‑Glance
- Founded: 2015
- Headquarters: Orange County, CA
- Focus: VHH discovery & platforms
- Engagements: FFS, licensing, co‑development
CaMouse VHH Platform
CaMouse is Akeagen’s proprietary rodent platform designed to generate heavy‑chain‑only antibodies in vivo, producing robust and diverse VHH repertoires from native immune responses.
Native In‑Vivo Maturation
Compatible with soluble proteins, complex membranes, cells, and difficult targets (GPCRs, ion channels).
Flexible Antigen Formats
Compatible with soluble proteins, complex membranes, cells, and difficult targets (GPCRs, ion channels).
Downstream‑Ready
Seamless progression to multivalent, bispecific, or Fc‑free constructs and half‑life extension modules.
Applications
- Therapeutic leads (oncology, inflammation, radiotheranostics)
- High‑sensitivity diagnostics and imaging
- Tool reagents and assay development
Integrated VHH Discovery Workflows
Phage Display
High‑throughput selection of VHH binders from immune or synthetic libraries using iterative panning strategies (solution, solid‑phase, or cell‑based).
- Deep diversity sampling across rounds
- Stringency tuning for affinity and specificity
- Parallelizable against multiple antigens
Yeast Display
Surface display of VHHs on S. cerevisiae enables multiparametric FACS selection for affinity, epitope binning, and developability attributes under screening stress.
- Quantitative affinity maturation via FACS
- Epitope and cross‑reactivity profiling
- Stress‑based sorting for stability & expression
Single B‑Cell Discovery
Direct recovery of native VHH sequences from antigen‑specific B cells using flow sorting and single‑cell sequencing for rapid, low‑bias hit identification.
- Maintains natural heavy‑chain‑only pairing
- Early insight into clonal families and SHM
- Fast path from antigen to recombinant VHH
mRNA Immunization
Rapidly elicits strong immune responses by delivering antigen‑encoding mRNA for in vivo expression, ideal for complex or difficult antigens. Shortens immunization cycles and broadens epitope coverage.
- Fast antigen production in situ
- Robust humoral response with diverse repertoires
- Compatible with membrane and multimeric targets
Contact us
Use the contact form if you have questions about our products. Our sales team will be happy to help you:
Offices
Akeagen, Inc.
Address:
23 Spectrum Pointe Dr
Suite 207
Lake Forest, CA 92630
Phone: +01 (949) 838-6753
Email: sunxl@akeagen.com
Trademark Notice: Nanobody® is a registered trademark of Ablynx NV, a Sanofi company. The term “nanobody” on this website is used solely as a generic reference to single‑domain antibody fragments and does not imply any affiliation, endorsement, or sponsorship by Ablynx NV or Sanofi.